The development of self-expanding stents dedicated to intracranial use has significantly widened the applicability of endovascular therapy to many intracranial aneurysms that would otherwise have been untreatable by endovascular techniques. Recent Food and Drug Administration approval of the Enterprise Vascular Reconstruction Device and Delivery System (Cordis) has added a new option for self-expanding stent-assisted intracranial aneurysm coiling.
The authors established a collaborative registry across multiple institutions to rapidly provide largevolume results regarding initial experience in using the Enterprise in real-world practice. Ten institutions (University at Buffalo, Thomas Jefferson University, University of Florida, Cleveland Clinic, Northwestern University, West Virginia University, University of Puerto Rico, Albany Medical Center Hospital, the Neurological Institute of Savannah, and the Barrow Neurological Institute) have provided consecutive data regarding their initial experience with the Enterprise.
In total, 141 patients (119 women) with 142 aneurysms underwent 143 attempted stent deployments. The use of Enterprise assistance with aneurysm coiling was associated with a 76% rate of ≥ 90% occlusion. An inability to navigate or deploy the stent was experienced in 3% of cases, as well as a 2% occurrence of inaccurate deployment. Procedural data demonstrated a 6% temporary morbidity, 2.8% permanent morbidity, and 2% mortality (0.8% unruptured, 12% ruptured).
The authors report initial results of the largest series to date in using the Enterprise for intracranial aneurysm treatment. The Enterprise is associated with a high rate of successful navigation and low occurrence of inaccurate stent deployment. The overall morbidity and mortality rates were low; however, caution should be exercised when considering Enterprise deployment in patients with subarachnoid hemorrhage as the authors' experience demonstrated a high rate of associated hemorrhagic complications leading to death.
Abbreviations used in this paper: FDA = Food and Drug Administration; HDE = Humanitarian Device Exemption; ICA = internal carotid artery; ICH = intracerebral hemorrhage; SAH = subarachnoid hemorrhage.
BendokBRParkinsonRJHageZAAdelJGGounisMJ: The effect of vascular reconstruction device-assisted coiling on packing density, effective neck coverage, and angiographic outcome: an in vitro study. Neurosurgery61:835–8412007
Food and Drug Administration: Cordis Enterprise Vascular Reconstruction Device and Delivery System. New Humanitarian Device Approval. H-60001. HUD Number: 04-0147(http://www.fda.gov/cdrh/mda/docs/H060001.html) [Accessed 9 April 2008]
GallasSDrouineauJGabrillarguesJPascoACognardCPierotL: Feasibility, procedural morbidity and mortality, and long-term follow-up of endovascular treatment of 321 unruptured aneurysms. AJNR Am J Neuroradiol29:63–682008
HigashidaRTHalbachVVDowdCFJuravskyLMeagherS: Initial clinical experience with a new self-expanding nitinol stent for the treatment of intracranial cerebral aneurysms: the Cordis Enterprise stent. AJNR Am J Neuroradiol26:1751– 17562005
KatsaridisVPapagiannakiCViolarisC: Embolization of acutely ruptured and unruptured wide-necked cerebral aneurysms using the Neuroform2 stent without pretreatment with antiplatelets: a single center experience. AJNR Am J Neuroradiol27:1123–11282006
WeberWBendszusMKisBBoulangerTSolymosiLKuhneD: A new self-expanding nitinol stent (Enterprise) for the treatment of wide-necked intracranial aneurysms: initial clinical and angiographic results in 31 aneurysms. Neuroradiology49:555–5612007